Karin Hehenberger, MD, PhD, will join the Board of Directors of Diamyd Medical as affiliated member, and be proposed for election to the Board at its next General Meeting of Shareholders. Dr. Hehenberger has a vast experience from both medical and financial executive positions within the fields of diabetes and other chronic diseases. Dr. Hehenberger has more than 20 years of experience in the life sciences sector, and is the CEO and founder of Lyfebulb. She served as an executive at Eyetech Pharmaceuticals (EYET) and Coronado BioSciences (CNDO) and had strategic management roles at Johnson & Johnson (Vice President Metabolic Strategy), JDRF (Senior Vice President Strategic Alliances), and McKinsey, as well as senior partnership roles at public (Brummer & Partners) and private (Scandinavian Life Science Ventures) multibillion dollar investment funds.